Ultragenyx Pharmaceutical (RARE) Shares Outstanding (Weighted Average) (2013 - 2026)

Ultragenyx Pharmaceutical (RARE) has 14 years of Shares Outstanding (Weighted Average) data on file, last reported at $100.6 million in Q1 2026.

• Quarterly Shares Outstanding (Weighted Average) rose 4.47% year-over-year to $100.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $100.6 million (up 4.47% YoY) and the FY2025 annual result came in at $98.6 million, up 8.95% from the prior year.
• Shares Outstanding (Weighted Average) improved to $100.6 million in Q1 2026 per RARE's latest filing, from $98.6 million in the prior quarter.
• Across five years, Shares Outstanding (Weighted Average) topped out at $100.6 million in Q1 2026 and bottomed at $3.2 million in Q2 2024.
• The 5-year median for Shares Outstanding (Weighted Average) is $73.5 million (2023), against an average of $78.4 million.
• The widest annual swing landed in 2024, when Shares Outstanding (Weighted Average) sank 95.48%; it then jumped 2971.88% in 2025.
• Tracing RARE's Shares Outstanding (Weighted Average) over 5 years: stood at $69.9 million in 2022, then advanced by 5.13% to $73.5 million in 2023, then increased by 23.13% to $90.5 million in 2024, then advanced by 8.95% to $98.6 million in 2025, then gained by 2.03% to $100.6 million in 2026.
• Per Business Quant, the three latest RARE Shares Outstanding (Weighted Average) figures stand at $100.6 million (Q1 2026), $98.6 million (Q4 2025), and $99.8 million (Q3 2025).

Peer Comparison